Emerging workplace health and safety threats—has the pandemic changed the trajectory?

Autor: Margaret M. Kitt

Publikováno v: Safety and Health at Work, Vol 13, Iss , Pp S2-S3 (2022)

Externí odkaz: https://doaj.org/article/0a9fba0067604e23abb1e683765f19aa

Genotypic investigation of a rotavirus cluster at a quaternary-care pediatric hospital

Autor: Eimear M. Kitt, Hee-won Yoon, Courtney E. Comar, Kenneth P. Smith, Rebecca M. Harris, Mathew D. Esona, Rashi Gautam, Slavica Mijatovic-Rustempasic, Amy L. Hopkins, Jose Jaimes, Lori K. Handy

Publikováno v: Infection Control & Hospital Epidemiology. :1-3

Rotavirus (RV) was a common healthcare-associated infection prior to the introduction of the RV vaccine. Following widespread RV vaccination, healthcare-associated rotavirus cases are rare. We describe an investigation of a cluster of rotavirus infec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::579759c219b2656b1f3b3b66fb6cf41f
https://doi.org/10.1017/ice.2022.317

Lmx1b is required at multiple stages to build expansive serotonergic axon architectures

Autor: Lauren J Donovan, William C Spencer, Meagan M Kitt, Brent A Eastman, Katherine J Lobur, Kexin Jiao, Jerry Silver, Evan S Deneris

Publikováno v: eLife, Vol 8 (2019)

Formation of long-range axons occurs over multiple stages of morphological maturation. However, the intrinsic transcriptional mechanisms that temporally control different stages of axon projection development are unknown. Here, we addressed this ques

Externí odkaz: https://doaj.org/article/6d9f90d5fd3a4607b0691a43da7cd864

Clinical experience with regadenoson SPECT myocardial perfusion imaging: insights into patient characteristics, safety, and impact of results on clinical management

Autor: Meredith Van Harn, Karthikeyan Ananthasubramaniam, Rita M Kristy, Yanqing Xu, Matthew A Saval, Therese M Kitt, James Spalding

Publikováno v: The International Journal of Cardiovascular Imaging. 38:257-267

The Henry Ford Hospital (HFH) regadenoson (REG) registry includes patients with a variety of comorbidities allowing for the evaluation of outcomes in a large, unselected population. Using a database of electronic medical records and nuclear cardiolog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a0e9e8e8240634a08114d3573645459
https://doi.org/10.1007/s10554-021-02374-1

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial

Autor: Fernando J, Martinez, Amna Sadaf, Afzal, Jaclyn A, Smith, Anthony P, Ford, Jerry Jing, Li, Yuping, Li, Michael M, Kitt, Murali, Ramaswamy

Publikováno v: Pulmonary Therapy
Chronic Cough in IPF Study Group, Martinez, F J, Afzal, A S, Smith, J A, Ford, A P, Li, J J, Li, Y & Kitt, M M 2021, ' Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial ', Pulmonary therapy . https://doi.org/10.1007/s41030-021-00162-9

Introduction Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d58682a6e9f33e7a4abb1f43461f81e0
https://doi.org/10.1007/s41030-021-00162-9